Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06981078 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Upstream Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 666
- Enrollment target
- 20
- Study locations
NCT06981078: Recruiting Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Upstream Bio.
NCT06981078 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Upstream Bio. The registered enrollment target is 666 participants, below the 1,746-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06981078, a Phase 2 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Upstream Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 666 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Verekitug
Study Locations (20)
California
- Kern Research Inc. - Bakersfield
- PulmoCrit Associates - Encino
- Torrance Clinical Research Institute - Lomita
- Dream Team Clinical Research - Pomona
- Apex Clinical Research - San Diego
- Allianz Research Institute - Westminster
Florida
- D&H Doral Research Center, LLC - Doral
- Qway Research, LLC - Hialeah
- Finlay Medical Research - Miami
- Research Institute of South Florida - Miami
- Florida Institute for Clinical Research,LLC - Orlando
Maryland
- Velocity Clinical Research-Rockville - Rockville
- Chesapeake Clinical Research, Inc - White Marsh
Colorado
- Allianz Research Institute - Aurora
Georgia
- Velocity Clinical Research-Savannah - Internal Medicine - Savannah
Illinois
- Christie Clinic, LLC - Champaign
Iowa
- The Iowa Clinic - West Des Moines
Minnesota
- HealthPartners - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 666 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
What NCT06981078 shows while recruiting
NCT06981078 is an interventional study that assigns participants to a tested intervention. The registered 666 participants enrollment target is mid-sized for trials with a published cap, below the 1,746-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06981078 names 20 study sites across 10 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06981078 about?
NCT06981078 is a clinical study titled "A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD". The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
What is the current status of trial NCT06981078?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 666 participants. The study started on 2025-07-02. Estimated completion is 2028-07.
What conditions does trial NCT06981078 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06981078?
The interventions under investigation include: Placebo (OTHER), Verekitug (DRUG).
Who is sponsoring clinical trial NCT06981078?
This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06981078 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06981078's enrollment target sits among peer trials
666 23rd of 86 higher than 64 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
-
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI